Skip to main content
. 2019 Aug 23;14(8):e0221413. doi: 10.1371/journal.pone.0221413

Fig 3. High VMP1 mRNA expression is correlated with shorter BCSS in cohort 1 and METABRIC.

Fig 3

Breast cancer specific survival (BCSS) was analyzed in (A) cohort 1, (B) cohort 2, (C) TCGA and (D) METABRIC. The patients were divided into two groups according to VMP1 mRNA levels: tumors expressing high VMP1 mRNA (high ≥ mean + 1 SD) and normal VMP1 (normal < mean + 1 SD). The log rank p-values are indicated in the figures. The number of patients at risk is shown below the graphs at the indicated timepoints. The median BCSS was 13.22 and 3.75 years for patients expressing normal and high VMP1 mRNA, respectively, in cohort 1, and 23.5 and 21.7 years in the METABRIC cohort. The hazard ratio (HR) for BCSS in cohort 1 was 2.31 (CI 1.27–4.18), and after adjusting for HER2 expression the HR was 2.03 (CI 1.00–3.72). In METABRIC HR was 1.26 (CI 1.02–1.57) and after adjusting for HER2 expression it was HR = 1.03 (CI 0.82–1.30).